Pure Biologics Spólka Akcyjna (PUR) - Total Liabilities

Latest as of September 2025: zł20.72 Million PLN ≈ $5.70 Million USD

Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has total liabilities worth zł20.72 Million PLN (≈ $5.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Pure Biologics Spólka Akcyjna long-term investment allocation to see how much of total assets are deployed in long-term investments.

Pure Biologics Spólka Akcyjna - Total Liabilities Trend (2016–2024)

This chart illustrates how Pure Biologics Spólka Akcyjna's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Pure Biologics Spólka Akcyjna assets under control.

Pure Biologics Spólka Akcyjna Competitors by Total Liabilities

The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their total liabilities.

Company	Country	Total Liabilities
Moatable Inc NYSE:MTBLY	USA	$38.09 Million
Batero Gold Corp V:BAT	Canada	CA$2.49 Million
Toyo Ventures Holdings Bhd KLSE:7173	Malaysia	RM214.75 Million
One Click Group Ltd AU:1CG	Australia	AU$1.03 Million
Courtois S.A PA:COUR	France	€9.50 Million
Korporacja Gospodarcza efekt S.A WAR:EFK	Poland	zł69.98 Million
Snipp Interactive Inc V:SPN	Canada	CA$13.42 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Pure Biologics Spólka Akcyjna's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PUR equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.06	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	15.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pure Biologics Spólka Akcyjna's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pure Biologics Spólka Akcyjna (2016–2024)

The table below shows the annual total liabilities of Pure Biologics Spólka Akcyjna from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	zł15.46 Million ≈ $4.25 Million	-25.84%
2023-12-31	zł20.84 Million ≈ $5.74 Million	+41.69%
2022-12-31	zł14.71 Million ≈ $4.05 Million	+90.97%
2021-12-31	zł7.70 Million ≈ $2.12 Million	-64.71%
2020-12-31	zł21.83 Million ≈ $6.01 Million	+49.80%
2019-12-31	zł14.57 Million ≈ $4.01 Million	+234.41%
2018-12-31	zł4.36 Million ≈ $1.20 Million	+290.25%
2017-12-31	zł1.12 Million ≈ $307.30K	+74.43%
2016-12-31	zł640.12K ≈ $176.17K	--

About Pure Biologics Spólka Akcyjna

WAR:PUR Poland Biotechnology

Market Cap

$8.33 Million

zł30.25 Million PLN

Market Cap Rank

#27602 Global

#301 in Poland

Share Price

zł2.67

Change (1 day)

-1.48%

52-Week Range

zł1.42 - zł7.00

All Time High

zł142.00